Human prostate cancers contain multiple cell populations marked by varying levels of the differentiation marker prostate-specific antigen (PSA). In this issue of Cell Stem Cell, Qin et al. (2012) show that PSA(-/lo) cells are enriched for cells with tumor-initiating characteristics and may participate in resistance to androgen-ablative therapies.